ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2022
Innovations in the prevention and treatment of postpartum hemorrhage: Analysis of a novel medicines development pipeline database.
Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A phase 1 evaluation of inhaled oxytocin: Physiologically-based pharmacokinetic model informed dosing of a novel heat-stable oxytocin delivery system.British journal of clinical pharmacology · 2026Trial
- Postpartum Hemorrhage: A Comprehensive Review of Medical and Surgical Treatment.Maternal-fetal medicine (Wolters Kluwer Health, Inc.) · 2026Review
- Bridging disciplinary siloes: a scoping review on the inclusion and exclusion of pregnant and lactating populations in clinical research.BMJ public health · 2026Article
- Identifying and assessing the capacity and experience of trial sites in low- and middle-income countries for high-quality randomised drug trials in maternal and perinatal health.BMJ global health · 2025Article
- Factors Influencing Pregnant Women's Participation in Randomised Clinical Trials in India: A Qualitative Study.BJOG : an international journal of obstetrics and gynaecology · 2025Article
- Uterotonic Drugs in Prevention and Management in Postpartum Haemorrhage in Prehospital Deliveries-A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- Article
- Research agenda for ending preventable maternal deaths from postpartum haemorrhage: a WHO research prioritisation exercise.BMJ global health · 2024Article
- Rational Design of Nanomedicine for Placental Disorders: Birthing a New Era in Women's Reproductive Health.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- The drug drought in maternal health: an ongoing predicament.The Lancet. Global health · 2024Review
- Landscape of toxin-neutralizing therapeutics for snakebite envenoming (2015-2022): Setting the stage for an R&D agenda.PLoS neglected tropical diseases · 2024Article
- New medicines for spontaneous preterm birth prevention and preterm labour management: landscape analysis of the medicine development pipeline.BMC pregnancy and childbirth · 2023Article
- Systematic evaluation of the pre-eclampsia drugs, dietary supplements and biologicals pipeline using target product profiles.BMC medicine · 2022Article
- Innovations in the prevention and treatment of postpartum hemorrhage: Analysis of a novel medicines development pipeline database.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA significant barrier to improving prevention and treatment of postpartum hemorrhage (PPH) is a lack of innovative medicines that meet the needs of women and providers, particularly those in low-and middle-income countries (LMICs). The Accelerating Innovation for Mothers (AIM) project established a new database of candidate medicines under development for five pregnancy-related conditions between 2000 and 2021.
objectiveTo systematically identify and rank candidates for prevention and treatment of PPH. SEARCH STRATEGY: Adis Insight, Pharmaprojects, WHO ICTRP, PubMed, and grant databases were searched to develop the AIM database. SELECTION CRITERIA: AIM database was searched for candidates being evaluated for PPH prevention and treatment, regardless of phase. DATA COLLECTION AND ANALYSIS: Candidates were ranked as high, medium, or low potential based on prespecified criteria. Analysis was primarily descriptive, describing candidates and development potential. MAIN
resultsOf the 444 unique candidates, only 39 pertained to PPH. One was high potential (heat-stable/inhaled oxytocin) and three were medium potential (melatonin, vasopressin and dofetilide via nanoparticle delivery).
conclusionThe pipeline for new PPH medicines is concerningly limited, lacking diversity, and showing little evidence of novel technologies. Without significant investment in early-phase research, it is unlikely that new products will emerge.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.